Evidence map›Paper›PMID 31192906›Full record

ArticleMedicine2019

Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis.

Chellan Kumarasamy, Shanthi Sabarimurugan, Royam Madhav Madurantakam, Kartik Lakhotiya, Suja Samiappan, Siddhratha Baxi, Ramesh Nachimuthu, Kodiveri Muthukaliannan Gothandam, Rama Jayaraj

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Diagnostic and prognostic role of NLR in testicular cancer.Exploration of targeted anti-tumor therapy · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chellan KumarasamyUniversity of Adelaide, North Terrace Campus, Australia.
Shanthi SabarimuruganSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
Royam Madhav MadurantakamSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
Kartik LakhotiyaSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
Suja SamiappanDepartment of Biochemistry, Bharathiyar University, Coimbatore, Tamil Nadu, India.
Siddhratha BaxiGenesis Cancer Care Centre, Bunbury, Western Australia.
Ramesh NachimuthuSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
Kodiveri Muthukaliannan GothandamSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
Rama JayarajCollege of Health and Human Sciences, Charles Darwin University, Darwin, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe neutrophil-lymphocyte-ratio, platelet-lymphocyte-ratio, and monocyte-lymphocyte-ratio have been explored as a simple, inexpensive, and effective method for cancer prognosis. However, there are no studies that have investigated the comparative utility of these markers, in multiple cancers.

methodsThe preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidelines were used to design this meta-analysis protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analyses. The core bibliographic database search will be carried out by 2 reviewers working individually, with each conducting an initial screening based on titles and abstracts. The shortlisted articles will be selected for review and quantitative analysis, based on predefined inclusion and exclusion criteria. Study characteristics, relevant clinicopathological characteristics, and statistical data required for meta-analysis (hazard ratios [HRs] and 95% confidence intervals [CIs]) will be extracted and compiled into a MS Excel datasheet. Meta-analysis will be performed, using a random-effects model, and the results (pooled HR and 95% CI) will be presented in the form of a forest plot. Publication bias will also be assessed by use of Egger bias indicator test and funnel plot symmetry. If statistical data from included studies is insufficient, a qualitative literature review will be pursued.PROSPERO registration: PROSPERO CRD42019121008.

Indexed as

BiomarkersHumansLeukocyte CountLymphocyte CountMeta-Analysis as TopicNeoplasmsNeutrophilsPlatelet CountPrognosisResearch DesignSurvival AnalysisSystematic Reviews as TopicBiomarkers

Identifiers

PMID31192906
PMCPMC6587598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.